MK-677 Explained: How to Maximize Muscle Gains (WITHOUT Screwing Up Insulin) · DadBod2Fit

MK-677 Explained: How to Maximize Muscle Gains (WITHOUT Screwing Up Insulin)

💸 Stop guessing prices.📊 Use my live price comparison tracker for Top Quality brands (with Discounts) 👇

🔗 https://price-compare-page--brianduclos4.replit.app/

MK-677 (Ibutamoren) blew up because it can boost growth hormone and IGF-1 — and IGF-1 is the piece that matters for bodybuilding because it supports recovery and the potential for new muscle tissue over time.

In this video, Brian and Chris (master’s in chemical sciences) break down how MK-677 works, why it spikes ghrelin (hunger hormone), how it keeps IGF-1 elevated longer than the dose itself, and how to structure your training nutrition so you’re not wasting the best part of the compound.

We also cover the part most people ignore: maximizing gains safely. If you’re using MK-677, the goal isn’t just “take it and hope.” The goal is to match higher IGF-1 with nutrient timing, keep your insulin sensitivity in a good place, and avoid common mistakes that lead to bloating, sloppy weight gain, or metabolic issues.

What you’ll learn in this video:

MK-677 basics: GH, IGF-1, and why it’s different from SARMs
Why MK-677 makes you hungry (ghrelin pathway) and how to use that
Why dosing strategy matters (slow ramp-up vs blasting day 1)
How to maximize gains with post-workout carbs + protein (nutrient timing)
2 common concerns with higher/longer use: prolactin + insulin resistance
The support stack discussion: P5P (prolactin support) + berberine (insulin sensitivity support)
Why bloodwork matters if you’re serious about performance and health

Important: This is educational content and personal experience — not medical advice. If you choose to use anything that impacts hormones/metabolism, do your own research and consider labs so you know what’s happening inside your body.

If you’ve used MK-677 before, comment your dose, timing, and what you noticed (hunger, sleep, recovery, water retention, strength, etc.).

22:32

0 comments